Company news

Precision BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

August 30, 2023

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

August 14, 2023

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 3, 2023

Precision BioSciences to Report Second Quarter Results on August 4, 2023

July 31, 2023

Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

July 26, 2023

Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

June 21, 2023

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

May 30, 2023

Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

May 11, 2023

Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

May 1, 2023

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

April 17, 2023

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

April 12, 2023

European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

March 21, 2023

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

March 8, 2023

Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

February 23, 2023

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

January 8, 2023

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

January 5, 2023

Precision BioSciences Announces Change to its Board of Directors

November 9, 2022

Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting

November 2, 2022

Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022

November 1, 2022

Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

October 25, 2022

Precision BioSciences Announces Senior Leadership Organizational Changes

September 1, 2022

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 7, 2022

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

July 31, 2022

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

June 26, 2022

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

June 20, 2022

Precision BioSciences Announces $50 Million Offering of Common Stock

June 20, 2022

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

June 7, 2022

Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022

June 2, 2022

Precision BioSciences Appoints Melinda Brown to Board of Directors

May 30, 2022

Precision BioSciences Appoints Juli Blanche as Chief People Officer

May 22, 2022

Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection

May 17, 2022

Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting

May 15, 2022

Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 8, 2022

Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

May 1, 2022

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

March 14, 2022

Precision BioSciences Completes Spin-Out of Elo Life Systems

December 20, 2021

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

December 10, 2021

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

December 5, 2021

Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors

November 7, 2021

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology

November 3, 2021

Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021

November 2, 2021

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

September 26, 2021

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

September 26, 2021

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

September 8, 2021

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

September 8, 2021

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

September 1, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

August 24, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 52 decks. Every deck is listed under its year.